Targeting Nucleic Acid Junctions with Small Molecules

用小分子靶向核酸连接

基本信息

批准号：
9706421
负责人：
David Michael Chenoweth
金额：
$ 10万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-20 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9706421
关键词：
Acids Address Affinity Aminoglycoside Antibiotics Animal Model Antibiotics Area Bacteria Base Pairing Binding Biological Biological Assay Biological Process Biology Biophysics Catalysis Catalytic RNA Chemicals Chromosome Structures Communicable Diseases Complement DNA Development Disease Drug Targeting Escherichia coli Evaluation Fluorescence Future Gene Expression Regulation Goals HIV Genome HIV/HCV Health Heat-Shock Response Human Immobilization In Vitro Intercalating Agents Libraries Macrolide Antibiotics Medical Medicine Messenger RNA Methods MicroRNAs Modern Medicine Modification Molecular Natural Products Neurodegenerative Disorders Nucleic Acids Outcome Outcomes Research Pathway interactions Process Property Proteins RNA RNA-Protein Interaction Reader Regulation Reporter Research Role Shapes Small Interfering RNA Specificity Structure Testing Tetracyclines Therapeutic Uses Trinucleotide Repeats United States National Institutes of Health Untranslated RNA Viral Genome Virus Replication base biological adaptation to stress biological systems combat design drug discovery frontier global health health economics high throughput screening human disease in vivo inhibitor/antagonist insight interest novel strategies nucleic acid structure nucleobase pathogen protein protein interaction repaired scaffold screening small molecule success therapeutic development tool

Acids Address Affinity Aminoglycoside Antibiotics Animal Model Antibiotics Area Bacteria Base Pairing Binding Biological Biological Assay Biological Process Biology Biophysics Catalysis Catalytic RNA Chemicals Chromosome Structures Communicable Diseases Complement DNA Development Disease Drug Targeting Escherichia coli Evaluation Fluorescence Future Gene Expression Regulation Goals HIV Genome HIV/HCV Health Heat-Shock Response Human Immobilization In Vitro Intercalating Agents Libraries Macrolide Antibiotics Medical Medicine Messenger RNA Methods MicroRNAs Modern Medicine Modification Molecular Natural Products Neurodegenerative Disorders Nucleic Acids Outcome Outcomes Research Pathway interactions Process Property Proteins RNA RNA-Protein Interaction Reader Regulation Reporter Research Role Shapes Small Interfering RNA Specificity Structure Testing Tetracyclines Therapeutic Uses Trinucleotide Repeats United States National Institutes of Health Untranslated RNA Viral Genome Virus Replication base biological adaptation to stress biological systems combat design drug discovery frontier global health health economics high throughput screening human disease in vivo inhibitor/antagonist insight interest novel strategies nucleic acid structure nucleobase pathogen protein protein interaction repaired scaffold screening small molecule success therapeutic development tool

展开

项目摘要

Summary: Despite significant advances in modern medicine and drug discovery there are still tremendous unmet medical needs for combating human disease. Infectious diseases and neurodegenerative diseases contribute to global health and economic problems of significant magnitude. Traditional drug discovery efforts focused on protein inhibitors are now being complemented by more non-traditional approaches such as targeting protein-protein interactions, once considered undruggable targets. RNA and RNA-protein interactions represent further examples of non-traditional drug targets with significant potential. This is primarily due to the central role of RNA in a diverse array of biological processes ranging from information transfer (mRNA) and gene regulation (siRNA's and microRNA's) to catalysis (ribozymes and riboswitches). The siRNA pathway and the diverse world of non-coding RNA's have regulatory functions ranging from cellular differentiation and chromosomal organization to the regulation of gene expression. The ability to target RNA-dependent processes represents an important challenge at the frontier of human medicine. Although not often thought of as a target for drug discovery, RNA targeting has been very successful in the case of antibiotics such as the aminoglycosides, tetracyclines, and macrolide antibiotics. Despite these successes, our ability to rationally design molecules to target some of the most important RNA structural motifs with high affinity and specificity is essentially non- existent. This proposal aims to develop structure specific nucleic acid modulators for targeting unmet medical needs. We will apply our newly developed nucleic acid modulators to target RNA dependent processes in E. coli, a pathogen and model organism of great interest to human health and the NIH.

概括：尽管现代医学和药物发现取得了重大进步打击人类疾病的需求。传染病和神经退行性疾病有助于全球健康和经济问题的重大问题。传统的药物发现工作重点是蛋白质现在，抑制剂正在通过诸如靶向蛋白质蛋白等更非传统方法的补充互动，曾经被认为是不良目标。 RNA和RNA - 蛋白质相互作用进一步代表具有巨大潜力的非传统药物靶标的示例。这主要是由于从信息传递（mRNA）和基因调控等各种生物学过程中的RNA （siRNA和microRNA）催化（核酶和核糖开关）。 siRNA途径和多样非编码RNA的世界具有从细胞分化和染色体的调节功能组织调节基因表达。靶向RNA依赖性过程的能力代表人类医学边界的一个重要挑战。虽然不经常被认为是毒品的目标在抗生素（例如氨基糖苷）的情况下，发现RNA的靶向非常成功，四环素和大环内酯类抗生素。尽管取得了这些成功，但我们能够合理设计分子的能力靶向一些具有高亲和力和特异性的最重要的RNA结构基序基本上是非 - 存在。该建议旨在开发结构特定的核酸调节剂，以靶向未完成医学需要。我们将应用新开发的核酸调节剂来靶向E的RNA依赖性过程。大肠杆菌，一种对人类健康和NIH兴趣极大兴趣的病原体和模型。